Free Trial
NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

$2.87
-0.06 (-2.05%)
(As of 05:17 PM ET)
Today's Range
$2.79
$2.95
50-Day Range
$2.14
$3.84
52-Week Range
$1.81
$7.74
Volume
262,975 shs
Average Volume
392,941 shs
Market Capitalization
$172.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Acumen Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
324.0% Upside
$12.00 Price Target
Short Interest
Healthy
2.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Acumen Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.13) to ($1.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

Medical Sector

530th out of 896 stocks

Biological Products, Except Diagnostic Industry

85th out of 152 stocks

ABOS stock logo

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ABOS Stock Price History

ABOS Stock News Headlines

China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
See More Headlines
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/20/2024
Today
7/19/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABOS
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$15.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+309.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-52,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.61 per share

Miscellaneous

Free Float
55,814,000
Market Cap
$176.03 million
Optionable
Optionable
Beta
0.10
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connell M.B.A. (Age 53)
    CEO & Director
    Comp: $901.2k
  • Mr. Matt Zuga
    CFO & Chief Business Officer
  • Mr. Derek M. Meisner Esq. (Age 53)
    J.D., Chief Legal Officer & Corporate Secretary
    Comp: $240.17k
  • Dr. James Doherty Ph.D. (Age 56)
    President & Chief Development Officer
  • Dr. Grant A. Krafft Ph.D.
    Co-Founder
  • Dr. Caleb E. Finch Ph.D.
    Co-Founder
  • Dr. William L. Klein Ph.D.
    Co-Founder
  • Mr. Russell Barton M.S. (Age 65)
    Chief Operating Officer
    Comp: $223.68k
  • Ms. Kelly Carranza
    Vice President, Finance & Accounting and Corporate Controller
  • Ms. Alex Braun M.B.A.
    VP & Head of Investor Relations

ABOS Stock Analysis - Frequently Asked Questions

How have ABOS shares performed this year?

Acumen Pharmaceuticals' stock was trading at $3.84 at the beginning of the year. Since then, ABOS shares have decreased by 26.3% and is now trading at $2.83.
View the best growth stocks for 2024 here
.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) issued its quarterly earnings results on Monday, May, 20th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02.

When did Acumen Pharmaceuticals IPO?

Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share.

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' top institutional investors include Gladius Capital Management LP (0.02%). Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Derek M Meisner, Russell Barton and Jeffrey L Ives.
View institutional ownership trends
.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABOS) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners